N-end rule pathway inhibition assists colon tumor regression via necroptosis

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Biology

Background:

• The N-end rule pathway degrades anti-survival proteins, preventing cell death.
• Inhibiting this pathway stabilizes pro-apoptotic proteins, sensitizing cells to programmed cell death.
• Receptor interacting serine-threonine protein kinase-1 (RIPK1) is crucial for necroptosis, an alternative cancer cell death pathway.

Purpose of the Study:

• To investigate the synergistic antitumor effect of a targeted liposome formulation combining an N-end rule inhibitor (RFC11) and shikonin.
• To explore the potential of necroptosis induction as a therapeutic strategy against cancer.
• To provide in vivo evidence for enhancing chemotherapy efficacy by inhibiting the N-end rule pathway.

Main Methods:

• Development of a biotin receptor-targeted liposome co-delivering RFC11 and shikonin.
• Evaluation of the formulation's efficacy in subcutaneous and orthotopic mouse colon tumor models.
• Assessment of RIPK1 upregulation and necroptosis induction as mechanisms of action.

Main Results:

• The targeted liposome formulation exhibited significant synergistic antitumor effects.
• Treatment induced necroptosis, characterized by RIPK1 upregulation.
• This study provides the first in vivo evidence that N-end rule pathway inhibition enhances conventional chemotherapeutic efficacy.

Conclusions:

• Targeted delivery of N-end rule inhibitors and chemotherapeutics can induce necroptosis for synergistic antitumor effects.
• Inhibition of the N-end rule pathway represents a promising strategy to overcome cancer's resistance to apoptosis.
• This approach offers a novel therapeutic modality for colon cancer treatment.